Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Phase I/IIa clinical trial for recessive dystrophic epidermolysis bullosa using EB-101 (COL7A1 gene-corrected autologous keratinocytes)

Phase I/IIa clinical trial for recessive dystrophic epidermolysis bullosa using EB-101 (COL7A1 gene-corrected autologous keratinocytes) Siprashvili, Z., Nguyen, N. T., Gorell, E. S., Loutit, K., Dutt-Singkh, Y., Nazaroff, J., Khuu, P., Furukawa, L., Lorenz, H. P., Leung, T. H., Keene, D. R., Rieger, K. E., Khavari, P. A., Lane, A. T., Tang, J. Y., Marinkovich, M. P. MARY ANN LIEBERT, INC. 2017: A10

View details for Web of Science ID 000418410700026